The ANCA vasculitis clinic nurse’s communication challenge
ANCA-associated vasculitis (AAV) encompasses granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis) and microscopic polyangiitis (MPA), both mediated by anti-neutrophil cytoplasmic antibodies directed against proteinase 3 (PR3-ANCA in GPA) or myeloperoxidase (MPO-ANCA in MPA). These antibodies activate primed neutrophils to produce the pauci-immune necrotizing small vessel vasculitis that is the pathological hallmark of AAV, affecting glomerular capillaries (producing rapidly progressive GN), pulmonary alveolar capillaries (producing alveolar hemorrhage), cutaneous venules (producing palpable purpura), and the microvasculature of the nasopharynx, sinuses, and subglottis (producing necrotizing granulomatous inflammation in GPA). AAV is potentially fatal without treatment and can produce permanent organ damage — dialysis-dependent ESRD, chronic lung fibrosis, subglottic stenosis requiring tracheostomy — within weeks of active disease if treatment is delayed or interrupted. The emergence of rituximab as the preferred induction and maintenance therapy for AAV in the past decade has transformed outcomes: the RAVE trial demonstrated rituximab non-inferiority to cyclophosphamide at six months with fewer serious adverse events in severe GPA, and the MAINRITSAN trial demonstrated that rituximab maintenance was superior to azathioprine maintenance in preventing major relapse, establishing rituximab as the standard of care for induction and maintenance in PR3-ANCA GPA and increasingly in MPO-ANCA MPA.
The communication failures in the ANCA vasculitis clinic cluster around three structural misunderstandings that are distinct from those in other autoimmune glomerular diseases. The first is the equation of ANCA titer normalization with disease cure: a patient whose PR3-ANCA or MPO-ANCA titer has become undetectable on rituximab concludes that the immune cells producing the pathogenic antibody have been permanently eliminated, not understanding that rituximab depletes CD20-positive B cells temporarily and that CD20-negative bone marrow progenitors reconstitute the B cell pool within six to twelve months, restoring the ANCA-producing clone in a substantial fraction of patients. The second is the misidentification of TMP-SMX rash and cessation of prophylaxis: a patient receiving rituximab plus high-dose corticosteroids — a combination that produces dual CD4 T cell depletion through B cell-dependent and steroid-dependent mechanisms — stops TMP-SMX when a rash appears without recognizing that the rash may be cushingoid acne from prednisone, that stopping TMP-SMX removes the only pharmacological barrier against Pneumocystis jirovecii pneumonia, and that PCP in this context can be fatal within days. The third is the resumption of smoking after achieving remission: a patient who quit smoking at AAV diagnosis resumes after achieving remission not knowing that cigarette smoke continuously primes neutrophils to express surface PR3 and MPO and induces NETosis that provides ongoing antigenic stimulation sustaining ANCA-producing B cell memory in the bronchus-associated lymphoid tissue, directly counteracting rituximab’s B cell suppression.
Three conversations from the ANCA vasculitis clinic:
Scenario 1: Alejandro Gómez-Reyes — 48 years old, Houston, Texas
Alejandro Gómez-Reyes was a high school history teacher in Houston who had presented to the emergency department with a two-month history of worsening nasal congestion, epistaxis, and facial pain, followed by new onset of hematuria with cola-colored urine and edema discovered incidentally during an urgent care visit for what he had attributed to a sinus infection. Initial labs showed creatinine 2.8 mg/dL with active urinary sediment: red cell casts, dysmorphic red blood cells, 2+ protein, and white cell casts. His chest CT showed bilateral upper-lobe cavitary lesions and nodules with surrounding ground-glass halo — the characteristic combination of necrotizing granulomas and pulmonary hemorrhage. A PR3-ANCA returned at 186 U/mL (strongly positive). He was admitted to nephrology for urgent kidney biopsy, which confirmed pauci-immune crescentic GN with 68 percent cellular crescents. Sinus biopsy confirmed necrotizing granulomatous inflammation with palisading histiocytes consistent with GPA. The diagnosis was clear: GPA with severe renal involvement and pulmonary manifestations requiring urgent treatment.
Alejandro received methylprednisolone 1 gram intravenously daily for three consecutive days, followed by oral prednisone 1 mg/kg/day. He was simultaneously started on rituximab 375 mg/m² intravenously weekly for four weeks per the RAVE protocol, with cyclophosphamide as a bridge for the first two months given the severity of his crescentic GN. He was started on TMP-SMX double-strength three times per week for PCP prophylaxis, calcium and vitamin D supplementation, and a proton pump inhibitor. He was counseled extensively by his nephrologist and rheumatologist on the disease mechanism, the treatment plan, and the monitoring schedule.
The induction phase proceeded well. At three months, his creatinine had fallen from 2.8 to 1.6 mg/dL. His PR3-ANCA had fallen from 186 to 52 U/mL. The hematuria had resolved. His pulmonary nodules were smaller on follow-up CT. His sinusitis had improved significantly on high-dose corticosteroids and rituximab. At six months, PR3-ANCA was 18 U/mL (borderline), creatinine 1.3 mg/dL, and he was in partial remission. Prednisone had been tapered to 5 mg daily. At twelve months, PR3-ANCA was 4 U/mL (approaching the lower limit of the assay), creatinine 1.2 mg/dL, and he was in clinical remission by BVAS criteria. He received his first rituximab maintenance dose of 500 mg intravenously, and a second dose at month thirteen. At eighteen months, PR3-ANCA was less than 2 U/mL — reported as “undetectable” on the clinical result. Creatinine was 1.2 mg/dL. His sinuses were clear on exam. He had returned to full-time teaching.
Alejandro came to the eighteen-month visit with a question he had been thinking about for weeks. He was feeling completely well. His blood tests showed the ANCA was undetectable. The creatinine was stable. He had done extensive research on GPA forums and had read case reports of patients who achieved sustained complete remission after two years and successfully stopped rituximab maintenance. He told his clinic nurse, Ana Torres-Espinoza, that he wanted to discuss with his rheumatologist whether the next scheduled maintenance dose at month eighteen was still necessary, and whether they might be approaching the point where the disease was “gone.”
Nurse Torres-Espinoza recognized the question as one she answered regularly with GPA patients achieving good responses: the visible indicators were excellent, but the inference about what they meant for disease permanence was precisely the one that led to preventable relapses. She asked whether she could walk him through what the undetectable ANCA result actually told them about the disease state, because that mechanism would inform whether “going well” meant the disease was resolved or suppressed.
She began with the ANCA result and what rituximab had done to produce it. Rituximab, she explained, was an antibody that targeted a protein called CD20 on the surface of mature B cells — the immune cells that produced the anti-PR3 antibody driving his GPA. When rituximab was given, it killed CD20-positive B cells through complement activation and by marking them for destruction by natural killer cells. The B cells that had been producing his PR3-ANCA were among those killed. Once those B cells were gone, circulating PR3-ANCA was cleared from the blood as its natural lifespan passed — IgG antibodies have a half-life of approximately three weeks, so repeated half-lives over months meant the circulating level fell toward zero. The undetectable result at eighteen months meant there was very little or no PR3-ANCA circulating in his blood at this moment. What it did not mean was that the immune cells with the memory and the capacity to produce that antibody had been permanently eliminated from his body.
The critical piece, Torres-Espinoza continued, was that CD20 was not expressed on the earliest bone marrow progenitors of B cells. The bone marrow stem cells that gave rise to new B cells did not carry CD20 yet — they only acquired CD20 at a later stage of B cell development. Rituximab could not reach these progenitors. From the moment of rituximab infusion, the bone marrow had been quietly generating new B cells from these CD20-negative precursors. B cell counts typically began recovering in the blood three to six months after rituximab, and full reconstitution was usually complete by twelve to eighteen months. Right now — at month eighteen — his B cell pool was likely substantially reconstituted. The question was whether, among all the new B cells being generated, any would develop into PR3-specific IgG-producing cells. If the PR3-ANCA-specific memory B cells had been stored in long-lived plasma cells or in committed bone marrow progenitors that survived the rituximab kill, those cells could re-emerge as the overall B cell population reconstituted and begin producing PR3-ANCA again.
In GPA specifically, she added, the relapse risk was substantially higher than in MPO-ANCA MPA. Published cohort data and the MAINRITSAN and RITAZAREM trial results consistently showed that PR3-ANCA-positive GPA had a major relapse rate of approximately forty to fifty percent within two years of stopping rituximab maintenance — compared to twenty to thirty percent in MPO-ANCA MPA. The MAINRITSAN trial, which compared rituximab 500 mg every six months for eighteen months versus azathioprine maintenance, demonstrated that rituximab maintenance was significantly better at preventing major relapse, with a relapse rate of approximately eighteen percent in the rituximab maintenance group versus forty percent in the azathioprine group at thirty-six months follow-up. The PR3-ANCA-positive subgroup had the greatest absolute benefit. These were the data behind the protocol he was on: the maintenance doses were not arbitrary — they were timed based on the B cell reconstitution window, specifically to retreat before the PR3-ANCA-producing clone fully re-established itself.
Torres-Espinoza then asked a question that shifted Alejandro’s frame: “¿Cuando tuvo la recaída que lo trajo a urgencias, em pezó con qué síntoma?” (When you had the flare that brought you to the emergency department, what symptom did it start with?) He described the hematuria — the cola-colored urine. She continued: “Cuando la creatinina llegó a 2.8 y había crecientes activas en el setenta por ciento de los filtros renales, ¿en qué momento del proceso estaba?” (When creatinine had reached 2.8 and there were active crescents in seventy percent of the renal filters, at what point in the process was that?) He understood: by the time the hematuria brought him to the emergency department, the vasculitis had already been destroying glomeruli for weeks. The creatinine was a late signal. Torres-Espinoza continued: “El anticuerpo ANCA sube semanas antes de que aparezca hematuria o de que suba la creatinina. Si lo monitorizamos cada tres meses y el anticuerpo empieza a subir, podemos tratar antes de que ningun glomérulo sea destruido. Si paramos el mantenimiento ahora y el clon de PR3 se regenera en seis meses, lo primero que note puede ser hematuria de nuevo — y para entonces el daño ya estará hecho.” (The ANCA antibody rises weeks before hematuria appears or creatinine rises. If we monitor it every three months and the antibody starts to rise, we can treat before any glomerulus is destroyed. If we stop maintenance now and the PR3 clone reconstitutes in six months, the first thing you notice may be hematuria again — and by then the damage will already be done.)
Alejandro received his month-eighteen maintenance rituximab dose and continued on the protocol. His PR3-ANCA remained undetectable through month twenty-two. At month twenty-four, a scheduled ANCA titer showed PR3-ANCA at 12 U/mL — rising but still below the positive threshold on the assay used at his center. His rheumatologist reviewed the trend and elected to give an additional 500 mg rituximab dose at month twenty-four rather than waiting for the scheduled month twenty-four dose, specifically to intervene at the earliest rise in ANCA before clinical activity re-emerged. His PR3-ANCA returned to 3 U/mL at month twenty-seven; creatinine remained stable at 1.2 mg/dL; there was no clinical relapse. The trend data had allowed pre-emptive retreatment precisely in the window when the rising ANCA predicted re-emerging B cell activity before tissue injury began.
Scenario 2: Carmen Espinoza-Torres — 61 years old, Los Angeles, California
Carmen Espinoza-Torres was a retired administrative coordinator in Los Angeles who had presented to nephrology after her primary care physician found creatinine 3.2 mg/dL and active urinary sediment on a routine metabolic panel drawn during an annual visit. She had noticed progressive fatigue and bilateral ankle swelling over the previous three months and had attributed both to the demands of caring for her grandchildren and to the humid summer. Her urinalysis showed 3+ blood, 2+ protein, and red cell casts. Her serum MPO-ANCA returned at 94 U/mL (strongly positive); PR3-ANCA was negative. Her chest CT showed bilateral patchy ground-glass opacities in the lower lobes. Kidney biopsy confirmed pauci-immune crescentic GN with thirty-five percent cellular crescents and fibrocellular crescents indicating both active and healing injury. The diagnosis was MPO-ANCA microscopic polyangiitis with renal involvement and subclinical pulmonary microhemorrhage.
Carmen was started on methylprednisolone 1 gram intravenously daily for three days followed by prednisone 1 mg/kg/day (60 mg daily) and rituximab 375 mg/m² intravenously weekly for four weeks per the RAVE induction protocol. She was started on TMP-SMX double-strength one tablet three times per week for PCP prophylaxis, given the combination of rituximab and high-dose corticosteroids creating the immunosuppressive environment associated with PCP risk in AAV treatment. She was also started on calcium 1200 mg with vitamin D 800 IU daily, omeprazole 20 mg daily, and blood pressure management with amlodipine 5 mg. She received extensive nursing education on her medications, the signs of infection requiring urgent evaluation, and the importance of all prophylactic medications including TMP-SMX.
Four weeks into treatment, Carmen called the rheumatology nursing line reporting a new skin rash. She described it as “granitos” (pimples) on her face, upper chest, and upper back that had appeared over the past ten days and were mildly uncomfortable but not pruritic. She had looked up TMP-SMX side effects online and had read about “drug rash” and was concerned that TMP-SMX was the cause. The nurse who took the call, Elena Gutiérrez-Morales, asked detailed questions about the rash: its distribution (face, upper chest, upper back), morphology (papulopustular — small raised lesions with white heads, not flat red patches), onset timeline (ten days into TMP-SMX and prednisone), presence of fever (none), presence of mucous membrane involvement (none), and pruritus (minimal, unlike the pruritic maculopapular rash typical of TMP-SMX hypersensitivity). The distribution and morphology nurse Gutiérrez-Morales heard were more consistent with steroid acne from the high-dose prednisone than with TMP-SMX hypersensitivity rash.
However, the clinic was fully booked that week, the covering physician was not available for a call-back that afternoon, and Carmen was emphatic that the rash was “from the antibiotics” and that she intended to stop TMP-SMX. Nurse Gutiérrez-Morales told her clearly that she should not stop TMP-SMX before speaking with the physician because the medication was protecting her against a serious lung infection, and asked Carmen to come in for a skin evaluation the following morning. Carmen agreed. That evening, she stopped TMP-SMX without informing the clinic, concluding that the rash was definitely from the medication and that she would discuss it at the morning appointment.
At the morning appointment, the rash was examined by the covering physician. The distribution was seborrheic — face (forehead, nose, perioral), upper chest, and upper back — with monomorphic closed comedones and open pustules with no target lesions, no urticarial plaques, no mucosal involvement, and no Nikolsky sign. This was consistent with steroid folliculitis (cushingoid acne) from high-dose prednisone, not TMP-SMX drug hypersensitivity. The physician recommended restarting TMP-SMX and reassured Carmen that the rash was from the cortisone, not the antibiotic. Carmen acknowledged understanding but did not restart TMP-SMX that day. Over the following two weeks, the TMP-SMX prescription was not refilled, and the clinic did not realize TMP-SMX had remained discontinued because the encounter note documented “patient educated, TMP-SMX restart recommended” and the prescription refill was assumed to have occurred.
Eleven weeks after TMP-SMX was stopped, Carmen called the rheumatology line reporting five days of progressive shortness of breath, dry cough, and fever to 38.6°C. She had been attributing the symptoms to a cold. Her oxygen saturation on the phone conversation was 88 percent by her home pulse oximeter. She was directed to the emergency department immediately. CT chest there showed bilateral diffuse ground-glass opacities in a perihilar pattern distinctly different from the patchy lower-lobe lesions seen on her MPA presentation CT. Bronchoalveolar lavage fluid was silver-stain positive for Pneumocystis jirovecii cysts. She was admitted to the medical ICU for Pneumocystis jirovecii pneumonia (PCP).
Carmen required high-flow oxygen at 40 liters per minute within six hours of admission and was intubated on day two for respiratory failure despite IV TMP-SMX 15 mg/kg/day plus adjunctive prednisone 40 mg BID for PCP-induced inflammatory response. She required mechanical ventilation for eighteen days. Her creatinine rose to 2.1 mg/dL during the acute illness from a combination of sepsis-associated hemodynamic changes and reduced effective circulating volume. She was eventually extubated and weaned to supplemental oxygen at 3 liters per nasal cannula, which she required for sixty days post-extubation before weaning to room air. Pulmonary function testing at six months after discharge showed a forced vital capacity of 78 percent predicted — a 22 percent reduction from the pre-hospitalization spirometry she had undergone at MPA diagnosis — reflecting permanent alveolar damage from the PCP episode. Her creatinine at discharge was 1.6 mg/dL and stabilized at 1.7 mg/dL at six months, measurably higher than the 1.1 mg/dL she had achieved before the PCP episode. Rituximab maintenance had to be delayed six months because of the infectious complication and the residual immunosuppression concerns.
Nurse Gutiérrez-Morales had a frank conversation with Carmen during the step-down unit stay, both to help Carmen understand what had happened and to prevent a recurrence on her future treatment course. She began by acknowledging that Carmen had heard that TMP-SMX might be causing the rash and that the instinct to stop something she thought was causing a side effect was completely understandable. The problem was that TMP-SMX was not like most medications — it was not treating a current infection. It was preventing a specific infection that only occurred in people whose immune system was suppressed in a very specific way, and whose lungs contained the dormant organism that TMP-SMX was blocking from multiplying.
Gutiérrez-Morales explained the mechanism. She described Pneumocystis jirovecii as a fungus that lived in the lungs of most adults without causing any disease, kept in check by CD4 T cells — a specific type of immune cell that activated the lung’s own defensive cells (alveolar macrophages) to control it. In people with a healthy immune system, CD4 T cells were abundant and Pneumocystis was harmless. But the combination of rituximab and prednisone had depleted Carmen’s CD4 T cells in two separate ways: rituximab had eliminated the B cells that helped maintain CD4 T cell populations through antigen presentation; and the prednisone at 60 mg daily had caused CD4 T cells to leave the circulation and reduced their number and function directly. The combined effect had lowered her functional CD4 T cell capacity below the threshold at which her alveolar macrophages could receive the activation signal needed to kill Pneumocystis. Without that signal, Pneumocystis had multiplied freely in her alveolar spaces, filling them with organisms and triggering the inflammatory response that had produced the bilateral ground-glass consolidation on CT. TMP-SMX worked specifically against Pneumocystis by blocking two steps in the organism’s ability to synthesize the building blocks it needed to replicate; no other antibiotic did this at the low prophylactic dose. When TMP-SMX was stopped, the block was removed, and the organism had eleven weeks to multiply to the density that produced respiratory failure.
“¿Eso significa que cuando me recetaron el Bactrim, era para una emergencia que no había ocurrido todavía?” Carmen asked. (Does that mean that when they prescribed Bactrim to me, it was for an emergency that had not happened yet?) Gutiérrez-Morales confirmed: “Exactamente. El Bactrim era la diferencia entre la presión arterial de oxígeno de 97% que tenía antes de pararlo y los dieciocho días en respirador que necesitó después de pararlo. Esa diferencia era una pastilla tres veces por semana.” (Exactly. The Bactrim was the difference between the 97% oxygen saturation you had before stopping it and the eighteen days on the ventilator you needed after stopping it. That difference was a tablet three times per week.) Carmen asked what she should do going forward when a medication caused a rash. Gutiérrez-Morales gave her the standing instruction she gave all AAV patients on immunosuppressive regimens: any new rash while on TMP-SMX required a same-day call to the nursing line before stopping the medication, because distinguishing steroid acne from drug rash was a clinical judgment that could not be made by the patient alone from the bathroom mirror, and the consequence of getting it wrong with TMP-SMX was not a mild side effect but an event that could require mechanical ventilation or cause death.
Scenario 3: José Luis Hernández-García — 54 years old, Phoenix, Arizona
José Luis Hernández-García was a construction company owner in Phoenix who had been diagnosed with limited GPA three years earlier, presenting with a two-year history of recurrent sinusitis with epistaxis, progressive nasal bridge collapse producing a saddle-nose deformity, and a recent episode of stridor and exertional dyspnea that had led to laryngoscopy revealing forty percent subglottic stenosis at the level of the cricoid ring. His PR3-ANCA was 87 U/mL at diagnosis. Kidney function was normal and there were no pulmonary infiltrates. Biopsy of the nasal mucosa showed necrotizing granulomatous inflammation consistent with GPA. He had no glomerulonephritis on urinalysis.
José Luis was treated with rituximab 375 mg/m² weekly for four weeks plus prednisone 1 mg/kg/day tapered over six months per the GPA induction protocol for limited disease (sparing cyclophosphamide given the absence of severe renal or pulmonary involvement). He was started on TMP-SMX prophylaxis and counseled on the importance of medication adherence. Importantly, he had smoked one pack per day for thirty-five years; his smoking history was forty pack-years. The rheumatologist counseled him explicitly at diagnosis that smoking was a specific risk factor for GPA relapse and that cessation was not optional but was a medical component of his treatment plan. José Luis had quit smoking at the time of his GPA diagnosis, supported by nicotine replacement therapy and a smoking cessation counselor, and had remained tobacco-free through his first two years of treatment.
He received rituximab maintenance doses of 500 mg every six months beginning at month six, with ongoing PR3-ANCA monitoring quarterly. His PR3-ANCA became undetectable at month twelve. Subglottic stenosis remained stable at forty percent — neither progressing nor fully resolving, a common course for GPA-related subglottic disease given that the structural narrowing from established scar tissue does not reverse with immunosuppression alone, though immunosuppression prevents additional scar formation. His sinuses were clear. He was in stable clinical remission.
At the eighteen-month clinic visit, José Luis disclosed to his clinic nurse, Marisol Cisneros-Gutiérrez, that he had started smoking again approximately three months earlier — initially just one or two cigarettes socially at work sites, which had escalated to one pack per day within six weeks. He framed it as something he felt embarrassed about but that seemed low risk because everything was going well with the GPA. The sinuses were clear. The ANCA was undetectable. He felt completely well.
Nurse Cisneros-Gutiérrez thanked him for disclosing it rather than concealing it and told him she wanted to be honest with him about what the cigarettes were doing inside his immune system and inside his airway right now, because the risk was not general health risk — it was mechanistically specific to GPA in a way that would change how he thought about it.
She began with the neutrophil mechanism. She explained that the PR3 protein whose antibody was causing his GPA normally lived inside the granules of his neutrophils — the white blood cells that were the engine of the vasculitic damage in GPA. Under normal circumstances, PR3 stayed inside the granule and was invisible to the immune system. But neutrophils could be “primed” — activated to move PR3 from the granule to the surface of the cell — by signals including inflammatory cytokines, bacterial products, and reactive oxygen species from cigarette smoke. When PR3 was on the cell surface, the anti-PR3 antibody (the PR3-ANCA that rituximab was suppressing) could bind to it and activate the neutrophil to attack the vessel wall. Cigarette smoke was one of the most potent inducers of neutrophil priming: every cigarette produced reactive oxygen species and nicotine-derived compounds in the lung that activated NF-kB in circulating neutrophils, causing PR3 to move from the granule to the surface. This was happening continuously — every pack of cigarettes he smoked was priming his neutrophils to display PR3, lowering the threshold of PR3-ANCA antibody needed to trigger vasculitic damage.
The second mechanism she described was specific to the airway. When neutrophils in the lung were primed by cigarette smoke, they underwent a process called NETosis — they died in a specific way that released their chromatin as long sticky threads into the airways. These neutrophil extracellular traps (NETs) carried PR3 embedded in the chromatin. In the bronchus-associated lymphoid tissue — clusters of immune cells in the airway wall that functioned like small lymph nodes — the PR3-decorated NETs were taken up by antigen-presenting cells that showed the PR3 to memory B cells nearby. Those memory B cells were the dormant version of the PR3-ANCA-producing clones that rituximab had suppressed. Every time they saw PR3, they were reminded of their target and their reactivation threshold was lowered. The rituximab maintenance doses were working to keep those B cells below their activation level; the cigarettes were continuously pushing them toward reactivation by providing ongoing PR3-antigen stimulation in the airway tissue.
Then she addressed the subglottic stenosis directly. She explained that the forty percent stenosis he had was a combination of active granulomatous inflammation and the scar tissue that had formed when the inflammation healed. The scar tissue itself did not reverse with medication — it was permanent structural narrowing. What rituximab was preventing was additional granulomatous inflammation that would produce additional scarring on top of the existing scar. Cigarette smoke caused direct inflammation of the subglottic mucosa through a mechanism entirely independent of ANCA vasculitis: the reactive oxygen species and irritant particles in cigarette smoke caused direct epithelial injury in the subglottis, activated goblet cell hyperplasia producing mucus that accumulated at the stenotic site, and recruited neutrophils locally that released proteases damaging the subglottic mucosa and stimulating fibroblast proliferation and collagen deposition — the scar-forming response. In the subglottis, where there was already forty percent scarring from his original GPA, the additional cigarette-smoke-driven fibroblast activation could close that airway faster than it would close with GPA alone. A patient with forty percent subglottic stenosis who smoked was giving the scar two reasons to grow rather than one.
Cisneros-Gutiérrez asked him: “¿Si le digo que en seis meses puede necesitar una dilatación de traquéa o incluso traqueostomía si el cigarrillo acelera la cicatriz, ¿cambia eso cómo piensa sobre el tabaco y la vasculitis?” (If I tell you that in six months you may need a tracheal dilation or even a tracheotomy if the cigarette accelerates the scar, does that change how you think about tobacco and the vasculitis?) José Luis was visibly affected. He had understood smoking cessation at diagnosis as a general health recommendation — similar to the cardiologist recommending it for heart disease. He had not understood that the cigarette was actively providing the mechanism that sustained his GPA, specifically in the airway where the scar was already growing.
He agreed to restart smoking cessation support. He was referred back to the cessation counselor he had worked with at diagnosis and was prescribed varenicline. At the twenty-one-month follow-up visit, three months after that conversation, he had stopped smoking again. His PR3-ANCA at month twenty-four was 8 U/mL — a rise from undetectable to just below positive. His rheumatologist added an additional rituximab dose at month twenty-four and increased monitoring frequency to every two months. Laryngoscopy at month twenty-four showed the subglottic stenosis had progressed slightly to approximately forty-five percent narrowing during the three months of smoking — a five-percentage-point increase requiring surveillance. With smoking cessation re-established and the rituximab maintenance continued, the subglottic stenosis stabilized at the twenty-seven-month follow-up and no additional dilation was required.
Frequently asked questions
How do ANCA vasculitis clinic nurses explain why rituximab maintenance must continue after PR3-ANCA or MPO-ANCA titers become undetectable?
The critical mechanistic point is that rituximab depletes CD20-positive mature B cells but cannot eliminate the CD20-negative bone marrow progenitors that reconstitute the B cell pool over six to twelve months. The PR3-ANCA or MPO-ANCA-producing B cell clone can re-emerge from reconstituting B cells, restoring ANCA production and ultimately triggering neutrophil activation and pauci-immune necrotizing vasculitis before the rising ANCA titer produces clinical symptoms. In PR3-ANCA GPA specifically — the highest-relapse subtype of AAV — published relapse rates off rituximab maintenance approach forty to fifty percent within two years, substantially higher than MPO-ANCA MPA. The MAINRITSAN trial demonstrated that rituximab 500 mg every six months reduced major relapse by thirty-six percent compared to azathioprine maintenance. An undetectable ANCA on rituximab maintenance is the drug suppressing the ANCA-producing B cell clone at this moment — it is not evidence that the immune program to produce ANCA has been permanently extinguished. The Spanish frame: “El ANCA indetectable significa que el rituximab está funcionando ahora mismo. Las células madre de la médula ósea están regenerando células B nuevas que podrían volver a producir el ANCA. El objetivo del mantenimiento es interceptar ese proceso antes de que el anticuerpo suba y los vasos sean atacados de nuevo.” (Undetectable ANCA means rituximab is working right now. Bone marrow stem cells are regenerating new B cells that could start producing ANCA again. The goal of maintenance is to intercept that process before the antibody rises and the vessels are attacked again.)
How do ANCA vasculitis clinic nurses explain why TMP-SMX prophylaxis must continue during rituximab and corticosteroid treatment?
Rituximab plus high-dose corticosteroids depletes functional CD4 T cells through two independent mechanisms: rituximab-induced B cell depletion reduces the antigen-presentation-driven CD4 T helper maintenance, and corticosteroids directly reduce CD4 T cell counts and function through redistribution and enhanced apoptosis. The combined CD4 depletion creates the functional equivalent of CD4 lymphopenia below the threshold at which alveolar macrophages cannot receive CD4 T cell activation signals needed to clear Pneumocystis jirovecii — a fungus that colonizes human airways at baseline without causing disease in immunocompetent individuals. TMP-SMX blocks both sequential steps of P. jirovecii folate synthesis (sulfamethoxazole blocks DHPS; trimethoprim blocks DHFR), providing specific prophylaxis against the opportunistic organism at three-times-weekly doses. Stopping TMP-SMX removes this protection; PCP in an AAV patient on rituximab and steroids carries mortality risk and commonly requires mechanical ventilation. The most dangerous error is stopping TMP-SMX for a rash that is actually steroid acne from concurrent prednisone rather than TMP-SMX drug hypersensitivity. The Spanish frame: “El Bactrim previene una infección pulmonar por hongo que solo ocurre cuando el sistema inmune está suprimido por rituximab y cortisona combinados. Si hay un sarpullido, llámenos antes de parar el Bactrim — la cortisona produce granos acnéicos en la cara que se confunden con alergia al Bactrim, y parar el Bactrim por ese error puede costar una neumonía grave.” (Bactrim prevents a lung fungal infection that only occurs when the immune system is suppressed by rituximab and cortisone combined. If there is a rash, call us before stopping Bactrim — cortisone produces acne-like pimples on the face that are confused with Bactrim allergy, and stopping Bactrim for that error can cost a serious pneumonia.)